Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 101 to 125 of 401 total

per page
Page:
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7

Catalog#SizeProduct NamePrice
60624 2 vials CD27 CHO-K1 Stable Recombiant Cell Line Contact us for pricing
79107 50 μg CD27(Mouse), Fc-Fusion (Human), Avi-Tag, Biotin
$405
71176 100 µg CD27, Fc fusion (Human)
$300
79067 100 μg CD27, Fc-Fusion (IgG1), Avi-Tag (Mouse) HiP™
$300
71113 200 µg CD28, Fc fusion (Human)
$295
72007 96 reactions CD28:B7-1[Biotinylated] Inhibitor Screening Assay Kit
$995
72062 96 reactions CD28:B7-2[Biotinylated] Inhibitor Screening Assay Kit
$995
71239 50 µg CD28H, Fc fusion, Biotin-labeled (Human) HiP™
$405
72511 50 μg CD30, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$405
71275 96 reactions CD38 Inhibitor Screening Assay Kit (Cyclase Activity)
$695
79287 96 reactions CD38 Inhibitor Screening Assay Kit (Hydrolase Activity)
$695
71277 100 μg CD38, His-Tag (Human), HiP™
$300
79070 100 μg CD38, His-Tag (Mouse), HiP™
$300
71883 100 μg CD38-APC, His-Tag
$300
79278 96 reactions CD39 Inhibitor Screening Assay Kit
$695
71284 50 µg CD39, His-Tag (Human)
$300
71174 100 µg CD40, Fc fusion (Human)
$300
79102 50 μg CD40, Fc Fusion (IgG1) Avi-Tag, Biotin Labeled
$405
60626 2 vials CD40/NF-κB Reporter (Luc) - HEK293 Recombinant Stable Cell Line Contact us for pricing
79258 384 reactions CD40:CD40L TR-FRET Assay
$995
79257 96 reactions CD40:CD40L[Biotinylated] Inhibitor Screening Assay Kit
$695
71191 100 µg CD40L (CD154), His-tag (Human)
$300
71187 100 µg CD44, Fc fusion (Human)
$300
71133 50 µg CD44, Fc fusion, Biotin-labeled (Human) HiP™
$405
71230 100 µg CD46-BC, His-tag (Human)
$300

Items 101 to 125 of 401 total

per page
Page:
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7